EGFR and non-small cell lung carcinoma: An ongoing phase Ib safety and pharmacodynamic study is being conducted with MRX-2843 in conjunction with osimertinib in patients with advanced EGFR-mutated NSCLC (NCT04762199) (Table 1) [159].